TP53 and acute myeloid leukemia: Thus, two new provisional entities (AML with mutated RUNX1 and AML with BCR-ABL1) have been included in the update of the WHO classification (3) and mutations in three genes (RUNX1, ASXL1 and TP53) have been added to the risk stratification of the 2017 ELN recommendation (2), which could guide new therapies (8).